The Phase 1b trial consisted of 24 patients with Parkinson’s disease, who received twice-weekly dosing of either HER-096 or placebo over a four-week period. The trial’s exploratory biomarker program ...
The Phase 1b trial consisted of 24 patients with Parkinson’s disease, who received twice-weekly dosing of either HER-096 or placebo over a four-week period. The trial’s exploratory biomarker program ...
LumiMind, a next-generation neurotechnology company focused on restoring the brain's natural rhythm, today announced the launch of LumiSleep at CES 2026 in Las Vegas. LumiSleep is the first-ever ...
Mom groups are meant to uplift and support, but these days, they feel more like a playground for toxic behaviour.
Bright Minds Biosciences (DRUG) stays a Strong Buy after Phase 2 BMB-101 seizure-reduction data; see 2026 catalysts, ...
Morning Overview on MSN
2027 Ram Power Wagon goes diesel with 1,000+ lb-ft
The 2027 Ram Power Wagon is finally getting the kind of diesel muscle fans have been asking for, and the headline figure is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback